Boehringer Ingelheim has presented data from a 6-week Phase 3 study of its tiotropium/olodaterol soft mist inhaler in 219 moderate to severe COPD patients showing that patients using the fixed dose combination had significantly greater improvements in FEV1 than those using either placebo or tiotropium or olodaterol monotherapy. Safety data were similar for the combination product compared to tiotropium alone.
University of Kiel Professor of Pulmonary Medicine Klaus R. Rabe commented, “The increase of more than 200 ml in trough FEV1 seen in the VIVACITO study with tiotropium + olodaterol FDC compared to placebo is significant. A few years ago we would simply not have thought this level of improvement would be possible.”
BI Pharmaceuticals Senior VP Clinical Development and Medical Affairs Tunde Otulana said, “As a leading provider of COPD treatment for the last decade, we are excited by these first data from TOviTO, our extensive clinical trial program for the tiotropium plus olodaterol fixed-dose combination, and look forward to presenting additional trial results later this year. Today, Boehringer Ingelheim has a diverse respiratory pipeline that includes several exciting developments for tiotropium.”
Read the BI press release.
